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Abstract
Lung cancer incidence in heart transplant patients is higher
than in general population and correlates with smoking history.
EGFR-mutations are more frequent in adenocarcinoma and
among non-smoking women but incidence in solid organ trans-
planted patients is still not known. We present case of a 65-year-
old ex-smoker male with history of heart transplantation and
EGFR positive metastatic lung adenocarcinoma. At admission he
was in a severe clinical condition and treatment with erlotinib was
started. Initially he had good clinical and radiologic response to
treatment with only grade 1 side effects. Data about drug interac-
tions between cyclosporine and erlotinib are insufficient but we
have to take this interaction into consideration during treatment
because both drugs are substrates and inhibitors of CYP34A. In
our case erlotinib was safe and well tolerated drug, there were no
relevant toxicity, but close monitoring and dose reduction of
cyclosporine was needed.
Introduction
Malignancies are one of the complications in transplant
patients and are now leading cause of mortality in this population
[1]. Among heart transplanted (HT) recipients incidence of lung
cancer is higher than in general population and correlates with
smoking history [2-5]. Frequency of epidermal growth factor
receptor (EGFR)-mutation is higher in adenocarcinoma, non-
smoking women and East Asian ethnicity [6]. There is no pub-
lished data in literature about frequency of EGFR positive patients
among solid organ transplanted patients.
Treatment options for lung cancer among transplanted patients
are the same as in the general population. Patients with EGFR pos-
itive lung carcinoma are treated with tyrosine kinase inhibitors
(TKI). Erlotinib is one of the TKI drugs and is mostly metabolized
by cytochrome P450 CYP3A4 and CYP1A1 [7]. Transplant
patients with lung cancer have shown poorer overall survival com-
pared to non-transplanted patients according to the limited data [8].
We report a case of HT patient with stage IV EGFR positive
lung adenocarcinoma treated with erlotinib. Erlotinib was well tol-
erated in combination with immunosuppressive therapy with no
clinically significant toxicity.
Case Report
A 65-year-old man, ex-smoker (40 pack/years), was admitted
to our Department after metastatic lung cancer was diagnosed
during his stay in Department of Cardiology. In April 2012 he
had heart transplantation due to ischemic cardiomyopathy and
was in a stable condition without signs of transplant rejection.
He was treated with cyclosporine, micophenolat-mophetyl and a
low dose of prednisolone as immunosuppressive therapy. His
first symptom was exertional dyspnea followed by dry cough,
low-grade fever, and he lost 15 kilograms till admission to
Department.
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At admission to our Department he was in a sever condition,
tachypneic (respiratory rate 30/min) and severely hypoxemic
with PaO2 33 mmHg. Laboratory test showed elevated urea level
18,9 mmol/L, creatinine level 132 µmol/L, LDH 884 U/L, C
reactive protein level 72.3 mg/L and other findings were within
normal limits.
His chest X-ray revealed bilateral interstitial lung changes at
the time of fist symptoms started. Heart transplant rejection and
infection were excluded by heart biopsy and there was no
improvement on antibiotic and antiviral treatment. Since his con-
dition get worse chest computed tomography (CT) scan was
done and it showed multiple micronodules 1 to 3 mm in diame-
ter, thickening of interlobular and intralobular septa and a fe w
areas of ground glass and bilateral small pleural effusions
(Figure 1). Bronchoscopy with bronchoalveolar lavage and
transbronchial biopsy was performed and pathology finding was
lung adenocarcinoma. Molecular analysis for EGFR mutations
showed mutation L858R on exon 21. According to the diagnostic
procedures definitive diagnosis was stage IV lung adenocarcino-
ma with lymphangiosis carcinomatosa of bo th lungs and bilateral
pleural carcinosis.
Despite his quite severe condition we decided to start treat-
ment with tyrosine kinase inhibitor (TKI) erlotinib since he had
EGFR L585R positive mutation. His condition improved after
only a week and he was discharged from the hospital.
One month after starting the treatment with erlotinib there
was no need for changing the dose of cyclosporine. He was
receiving 70 mg cyclosporine twice daily and his cyclosporine
blood level was between 80 and 90 µg/L. After that his
cyclosporine blood level started to rise above targeted level of
100 µg/L and the highest blood level of cyclosporine was above
220 µg/L. Cyclosporine dose was gradually reduced and three
months after starting erlotinib the dose of cyclosporine was 40
mg in the morning and 30 mg in the evening.
Chest CT revealed significant reduction of interstitial and
micronodular lung changes (Figure 2) with clinical improvement
and oxygen level on room air of 74 mmHg two months after
beginning of the treatment. He had only grade 1 skin side effects
and diarrhea for only two days during the first month of treatment
without erlotinib side effects during further treatment.
Unfortunately four months after beginning of treatment, pro-
gression of left sided pleural effusion and interstitial opacities
was revealed on chest X-ray and his condition was severely dete-
riorated. Erlotinib treatment was stopped and he died about four
and a half months after establishing the diagnosis and starting the
treatment.
                             Case Report
Figure 1. Chest CT scan before definitive diagnosis was estab-
lished: multiple micronodules 1 to 3 mm in diameter, thickening
of interlobular and intralobular septa with few areas of ground
glass and minimal bilateral pleural effusions.
Figure 2. Comparison of CT scan before treatment (A) and two months after treatment (B).
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Discussion
Nowadays we have longer allograft survival due to advances in
immunosuppressive regiments which leads to collateral emergence
of long-term post-transplant complications and malignancies are
one of the most frequent.
Lung cancer is one of the most frequent malignancies in heart
transplanted patients [4]. In heart transplant recipients’, higher
incidence of lung cancer is not necessarily a consequence of the
immunosuppression therapy because we can approach to these
patients as a selected group of patients who have another risk fac-
tor like cigarette smoking. In published data cigarette smoking is
linked to lung cancer development in heart transplant recipients
which can be explained by augmentation of ischemic heart failure
caused by tobacco consumption as a background factor of the heart
transplantation [3].
Most of the published studies showed that lung cancer in organ
transplant recipients is presented in late stage of disease [1,4]. Our
patient correlate with that because at admission he had stage IV of
lung cancer although he had frequent monitoring after transplanta-
tion. Treatment approach in heart transplanted patient is the same
as in general population and it depends on histologic type of the
tumor, mutation status, stage of the disease and patient’s perform-
ance status. In our case, according to mutation status where we had
EGFR L585R positive mutation, treatment with TKI was indicat-
ed. We decided to start treatment with erlotinib in spite of poor per-
formance status and severe respiratory insufficiency. One of the
things that differs this group of patients from general population is
immunosuppressive therapy that they are taking. In our case
cyclosporine and micophenolat-mophetyl were two drugs that we
have to consider for possible drug interactions with erlotinib.
Cyclosporine is, like erlotinib, CYP3A4 substrate but it also
inhibits CYP3A4. Review of the literature about potential interac-
tions between cyclosporine and erlotinib gave us only one pub-
lished paper. De Pas et al. published that the use of cyclosporine is
not a contraindication for treatment with erlotinib according to
their experience and there was no relevant toxicity [9]. In their case
they had to increase dose of the cyclosporine but in contrary we
had to reduce it. We can assume that in our case erlotinib as a
CYP34A inhibitor [7] increased the blood level of cyclosporine.
Erlotinib was well tolerated in both cases and patients had only
grade 1 side effects. It is important to notice that side effects have
to be monitored more closely in these patients because
cyclosporine is also CYP3A4 inhibitor and blood level of erlotinib
can be increased because of that.
In registration studies for tyrosine kinase inhibitors median
progression free survival was 9 to 11 months [10]. In our case we
only have 4 months of treatment before disease progression.
Zambrano Medoza et al. also published a case of early progression
of EGFR positive lung adenocarcinoma in heart transplanted recip-
ient after only 2 months of treatment with erlotinib [11]. This can
be explained by advanced disease at the beginning of the treatment
but there may be some other factors like immunosuppression ther-
apy that influenced this on what we do not have any available data.
In our case we did not check plasma concentration of erlotinib.
So far, we still do not know the incidence of EGFR positive
patients among solid organ transplanted patients. In era of new
treatment options and longer survival of solid organ transplanted
patients we have to think about possible new drug interactions.
Conclusions
We can conclude that the use of erlotinib in solid organ trans-
planted patients treated with cyclosporine is safe and without any
clinically relevant toxicity. From our experience and previously
published date we recommend close monitoring of blood level of
cyclosporine and erlotinib side effects.
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